Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-08-29 Sale | 2024-09-03 5:43 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $22.49 | $269,841 | 1,077,936 (Indirect) | View |
| 2024-08-27 Sale | 2024-08-29 6:36 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $22.54 | $95,782 | 199,129 (Direct) | View |
| 2024-08-26 Sale | 2024-08-28 7:48 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $22.89 | $274,718 | 1,049,255 (Indirect) | View |
| 2024-08-15 Sale | 2024-08-19 7:49 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $23.25 | $29,526 | 195,698 (Indirect Direct) | View |
| 2024-07-31 Sale | 2024-08-02 7:26 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 3,099 | $27.56 | $85,399 | 1,089,936 (Indirect) | View |
| 2024-07-31 Sale | 2024-08-02 7:25 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 2,270 | $27.56 | $62,555 | 1,061,255 (Indirect) | View |
| 2024-07-31 Sale | 2024-08-02 7:23 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $27.53 | $27,281 | 203,379 (Direct) | View |
| 2024-07-31 Sale | 2024-08-02 7:22 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 2,351 | $27.5 | $64,663 | 196,968 (Indirect Direct) | View |
| 2024-07-29 Sale | 2024-07-31 7:33 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $26.7 | $320,378 | 1,093,035 (Indirect) | View |
| 2024-07-29 Sale | 2024-07-31 7:31 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $26.68 | $140,052 | 204,370 (Direct) | View |
| 2024-07-25 Sale | 2024-07-29 5:39 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $24.92 | $299,073 | 1,240,587 (Indirect) | View |
| 2024-07-15 Sale | 2024-07-17 7:25 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $24.8 | $31,497 | 199,319 (Indirect Direct) | View |
| 2024-07-12 Sale | 2024-07-16 5:37 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 50,000 | $25.06 | $1,252,826 | 344,027 (Indirect) | View |
| 2024-07-12 Sale | 2024-07-16 5:34 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $25.07 | $75,195 | 209,620 (Direct) | View |
| 2024-07-01 Sale | 2024-07-03 4:31 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $22.89 | $274,736 | 1,105,035 (Indirect) | View |
| 2024-06-27 Sale | 2024-07-01 8:03 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $22.57 | $95,922 | 212,620 (Direct) | View |
| 2024-06-25 Sale | 2024-06-27 4:35 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $21.66 | $259,902 | 1,252,587 (Indirect) | View |
| 2024-06-17 Sale | 2024-06-20 7:20 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $21.48 | $27,278 | 200,589 (Indirect Direct) | View |
| 2024-06-06 Sale | 2024-06-10 6:46 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,133 | $20.06 | $22,722 | 447,369 (Indirect Direct) | View |
| 2024-05-29 Sale | 2024-05-31 4:05 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $21.73 | $260,800 | 1,323,585 (Indirect Direct) | View |
| 2024-05-28 Sale | 2024-05-30 5:56 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $23.18 | $278,210 | 1,453,428 (Indirect Direct) | View |
| 2024-05-28 Sale | 2024-05-30 5:54 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $23.18 | $98,530 | 216,870 (Direct) | View |
| 2024-05-16 Sale | 2024-05-20 7:46 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 1,270 | $23.74 | $30,150 | 201,859 (Indirect Direct) | View |
| 2024-05-16 Sale | 2024-05-20 5:03 pm | Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner | 1,033,300 | $22.14 | $22,877,262 | 7,663,349 (Indirect) | View |
| 2024-05-16 Sale | 2024-05-20 5:00 pm | Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner | 1,033,300 | $22.14 | $22,877,262 | 7,663,349 (Indirect) | View |
| 2024-05-14 Sale | 2024-05-16 7:29 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,107 | $25 | $27,675 | 448,502 (Indirect Direct) | View |
| 2024-05-09 Sale | 2024-05-13 7:35 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 260 | $25.06 | $6,515 | 449,609 (Indirect Direct) | View |
| 2024-05-06 Sale | 2024-05-08 8:40 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $22.72 | $110,769 | 449,869 (Indirect Direct) | View |
| 2024-05-03 Sale | 2024-05-07 6:58 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $22.5 | $22,500 | 221,120 (Direct) | View |
| 2024-04-29 Sale | 2024-05-01 7:04 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $17.92 | $214,988 | 1,335,585 (Indirect Direct) | View |
| 2024-04-29 Sale | 2024-05-01 7:02 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $16.97 | $55,165 | 222,120 (Direct) | View |
| 2024-04-25 Sale | 2024-04-29 6:50 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $16.89 | $202,700 | 1,465,428 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:06 pm | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 17,500 | $25.03 | $438,099 | 454,744 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:06 pm | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $25.04 | $751,332 | 1,347,585 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:05 pm | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $25.04 | $1,194,700 | 1,477,428 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:04 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $24.72 | $346,149 | 225,370 (Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:03 pm | Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director | 6,964 | $24.11 | $167,888 | 203,129 (Indirect Direct) | View |
| 2024-04-11 Sale | 2024-04-15 7:02 pm | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $25.07 | $501,478 | 267,084 (Direct) | View |
| 2024-04-10 Sale | 2024-04-12 6:23 pm | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 67,000 | $23.36 | $1,564,812 | 146,903 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-08-27 Exercise | 2024-08-29 6:36 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 199,129 (Direct) | View |
| 2024-08-27 Exercise | 2024-08-29 6:36 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 199,129 (Direct) | View |
| 2024-07-31 Exercise | 2024-08-02 7:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $2.48 | 203,379 (Direct) | View |
| 2024-07-31 Exercise | 2024-08-02 7:23 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 991 | $0 | 203,379 (Direct) | View |
| 2024-07-29 Exercise | 2024-07-31 7:31 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $2.48 | 204,370 (Direct) | View |
| 2024-07-29 Exercise | 2024-07-31 7:31 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 5,250 | $0 | 204,370 (Direct) | View |
| 2024-07-12 Exercise | 2024-07-16 5:34 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $2.48 | 209,620 (Direct) | View |
| 2024-07-12 Exercise | 2024-07-16 5:34 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,000 | $0 | 209,620 (Direct) | View |
| 2024-06-27 Exercise | 2024-07-01 8:03 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 212,620 (Direct) | View |
| 2024-06-27 Exercise | 2024-07-01 8:03 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 212,620 (Direct) | View |
| 2024-06-06 Exercise | 2024-06-10 6:46 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,133 | $2.48 | 447,369 (Direct) | View |
| 2024-06-06 Exercise | 2024-06-10 6:46 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,133 | $0 | 447,369 (Direct) | View |
| 2024-05-29 Exercise | 2024-05-31 4:05 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,323,585 (Direct) | View |
| 2024-05-29 Exercise | 2024-05-31 4:05 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,323,585 (Direct) | View |
| 2024-05-28 Exercise | 2024-05-30 5:56 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,453,428 (Direct) | View |
| 2024-05-28 Exercise | 2024-05-30 5:56 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,453,428 (Direct) | View |
| 2024-05-28 Exercise | 2024-05-30 5:54 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $2.48 | 216,870 (Direct) | View |
| 2024-05-28 Exercise | 2024-05-30 5:54 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 4,250 | $0 | 216,870 (Direct) | View |
| 2024-05-14 Exercise | 2024-05-16 7:29 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,107 | $2.48 | 448,502 (Direct) | View |
| 2024-05-14 Exercise | 2024-05-16 7:29 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 1,107 | $0 | 448,502 (Direct) | View |
| 2024-05-09 Exercise | 2024-05-13 7:35 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 260 | $2.48 | 449,609 (Direct) | View |
| 2024-05-09 Exercise | 2024-05-13 7:35 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 260 | $0 | 449,609 (Direct) | View |
| 2024-05-06 Exercise | 2024-05-08 8:40 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $2.48 | 449,869 (Direct) | View |
| 2024-05-06 Exercise | 2024-05-08 8:40 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 4,875 | $0 | 449,869 (Direct) | View |
| 2024-05-03 Exercise | 2024-05-07 6:58 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $2.48 | 221,120 (Direct) | View |
| 2024-05-03 Exercise | 2024-05-07 6:58 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 1,000 | $0 | 221,120 (Direct) | View |
| 2024-04-29 Exercise | 2024-05-01 7:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $1.12 | 1,335,585 (Direct) | View |
| 2024-04-29 Exercise | 2024-05-01 7:04 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 12,000 | $0 | 1,335,585 (Direct) | View |
| 2024-04-29 Exercise | 2024-05-01 7:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 222,120 (Direct) | View |
| 2024-04-29 Exercise | 2024-05-01 7:02 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 222,120 (Direct) | View |
| 2024-04-25 Exercise | 2024-04-29 6:50 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $1.12 | 1,465,428 (Direct) | View |
| 2024-04-25 Exercise | 2024-04-29 6:50 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 12,000 | $0 | 1,465,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 14,903 | $2.48 | 454,744 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A 2031-03-25 | Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER | 14,903 | $0 | 454,744 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $1.12 | 1,347,585 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:06 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 30,000 | $0 | 1,347,585 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:05 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $1.12 | 1,477,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:05 pm | N/A 2030-06-16 | Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO | 47,709 | $0 | 1,477,428 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $2.48 | 225,370 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $0 | 225,370 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $2.48 | 267,084 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:02 pm | N/A 2031-06-17 | Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER | 20,000 | $0 | 267,084 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-12 6:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 4,580 | $19.68 | 146,903 (Direct) | View |
| 2024-04-10 Exercise | 2024-04-12 6:23 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 62,420 | $12.6 | 146,903 (Direct) | View |
| 2024-04-10 Exercise | 2024-04-12 6:23 pm | N/A 2028-10-19 | Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director | 67,000 | $0 | 146,903 (Direct) | View |
| 2024-04-08 Option Award | 2024-04-10 8:39 pm | N/A 2034-04-08 | Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director | 37,882 | $0 | 37,882 (Direct) | View |